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OBJECTIVE We sought to assess the activity of endogenous endothelin-1 (ET-1) in hypercholesterolemic
patients using antagonists of ET-1 receptors.
BACKGROUND Endothelial dysfunction in hypercholesterolemic patients may contribute to their risk of
premature atherosclerosis. Endothelin, a peptide released by endothelial cells, may be
involved in this process by activating smooth muscle cell mitogenesis and leukocyte adhesion.
METHODS Forearm blood flow (FBF) responses (strain-gauge plethysmography) to intra-arterial
infusion of a selective blocker of ETA receptors (BQ-123) and, on a separate occasion, to
ET-1 were measured in 12 hypercholesterolemic patients and 12 normal control subjects. In
addition, on a different day, six hypercholesterolemic patients received co-infusion of BQ-123
and BQ-788 (a selective blocker of ETB receptors).
RESULTS In normal subjects, BQ-123 did not significantly modify FBF from baseline (p 5 0.78);
however, in hypercholesterolemic patients, BQ-123 administration resulted in a significant
vasodilator response (p , 0.001). Administration of exogenous ET-1 resulted in similar
vasoconstrictor responses in patients (37%) and control subjects (35%) (p 5 0.83). In
hypercholesterolemic patients, the vasodilator response to selective ETA blockade was
reversed by nonselective blockade of ET-1 receptors obtained by co-infusion of BQ-123 and
BQ-788.
CONCLUSIONS The vascular activity of endogenous ET-1 is enhanced in hypercholesterolemic patients,
whereas their sensitivity to exogenous ET-1 is unchanged. These findings suggest increased
production of ET-1, which may participate in the pathophysiology of vascular disease
characteristic of hypercholesterolemia. (J Am Coll Cardiol 2000;36:1483–8) © 2000 by the
American College of Cardiology
The endothelium plays an important role in vascular ho-
meostasis by synthesizing and releasing a number of sub-
stances that modulate vascular tone and structure and the
interactions of circulating cells with the vessel wall (1).
Patients with hypercholesterolemia have endothelial dys-
function, expressed as decreased nitric oxide (NO)–
dependent vasodilator responsiveness to acetylcholine (2,3),
which may contribute to their risk of premature atheroscle-
rosis.
Previous studies in experimental models have suggested
that endothelin-1 (ET-1), another substance secreted by
endothelial cells, may also be involved in the vasomotor
dysregulation of hypercholesterolemia (4). Endothelin-1 is a
21-amino acid peptide that exerts its vascular effects via
specific binding to two receptor subtypes: ETA and ETB
(5,6). On vascular smooth muscle cells, both ETA and ETB
receptors mediate vasoconstriction (7,8), whereas ETB re-
ceptors on endothelial cells cause vasodilation, predomi-
nantly through activation of the L-arginine-NO pathway
(9). In addition to its vasoactive properties, ET-1 also
induces smooth muscle cell mitogenesis (10,11), leukocyte
adhesion (12) and monocyte chemotaxis (13), thereby im-
plying a potential involvement of this peptide in the
initiation and/or the progression of the atherosclerotic
process.
Evidence of activation of the ET-1 system in hypercho-
lesterolemia, and of a potential role of ET-1 in atheroma-
tous vascular disease, stems from studies performed both in
experimental models and in humans. Thus, plasma immu-
noreactive ET-1 is increased in rats (14) and pigs (15) fed a
high-cholesterol diet. Also, oxidized low density lipopro-
teins stimulate the expression of prepro-ET-1 messenger
RNA and the release of ET-1 in cultured endothelial cells
(16). In humans, the presence of immunoreactive ET-1 has
been demonstrated in smooth muscle and endothelial cells
at the sites of atherosclerotic lesions (17). Moreover, in
keeping with the results of animal studies, plasma ET-1
levels are elevated in patients with hypercholesterolemia
(18,19). The relevance of increased plasma levels as an
expression of the vascular activity of the ET-1 system is,
however, questionable because the peptide acts predomi-
nantly in an autocrine and paracrine manner and its secre-
tion by endothelial cells is polarized toward the underlying
vascular smooth muscle (20). Consequently, plasma ET-1
levels may not necessarily reflect endothelial cell production
or its biological effect on smooth muscle cells. Recently,
selective and nonselective blockers of ET-1 receptors have
become available for clinical studies and provide a more
meaningful tool to assess the role of ET-1 in vascular
homeostasis in vivo. The present study, therefore, was
designed to determine whether the activity of the ET-1
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system is increased in the forearm resistance vessels of
hypercholesterolemic patients using specific blockers of
ET-1 receptors.
METHODS
Study subjects. Twelve patients (Table 1) were recruited
for this study. Patients were selected on the basis of elevated
plasma cholesterol levels (.250 mg/dl) at the time of a
screening visit at the outpatient clinic of the National Heart,
Lung, and Blood Institute (NHLBI). Patients were ex-
cluded from this study if they had a history of diabetes,
hypertension, coronary or peripheral vascular disease, myo-
cardial infarction, stroke, coagulopathy or any disease pre-
disposing them to vasculitis or Raynaud’s phenomenon.
Eight patients had never been treated with lipid-lowering
drugs; the remaining four patients discontinued their med-
ications (statins in three patients and cholestyramine in one
patient) for four weeks before enrollment into this study.
Twelve normal volunteers matched with the patients for
approximate race, gender and age were selected as a control
group (Table 1). Each subject was screened by clinical
history, physical examination, electrocardiograph (ECG)
chest X-ray and routine chemical analyses. None had
evidence of present or past hypertension, hyperlipidemia,
cardiovascular disease or any other systemic condition.
None of the study participants was taking any medication
at the time of the study. In particular, all patients and
control subjects were asked to refrain from taking vitamin
supplements for four weeks, aspirin for two weeks and
smoking and caffeine for at least 24 h before the study.
The study protocol was approved by the NHLBI Inves-
tigational Review Board, and all participants gave written
informed consent.
Protocols. All studies were performed in the morning in a
quiet room with a temperature of approximately 22°C. Each
study consisted of infusion of drugs into the brachial artery
and measurement of the response of the forearm vasculature
by means of strain-gauge venous occlusion plethysmogra-
phy. All drugs utilized in this study were approved for
investigational use in humans by the Food and Drug
Administration and were prepared by the Pharmaceutical
Development Service of the National Institutes of Health
following specific procedures to ensure accurate bio-
availability and sterility of the solutions.
While the participants were in supine position, a 20-
gauge Teflon catheter (Arrow Inc.; Reading, Pennsylvania)
was inserted into the brachial artery of the nondominant
arm (left in most cases). This arm was slightly elevated
above the level of the right atrium, and a mercury-filled
silicone rubber strain-gauge was placed in the widest part of
the forearm (21). The strain-gauge was connected to a
plethysmograph (model EC-4; D.E. Hokanson; Bellevue,
Washington), calibrated to measure the percent change in
volume and connected in turn to a chart recorder. For each
measurement, a cuff placed around the upper arm was
inflated to 40 mm Hg with a rapid cuff inflator (model
E-10; Hokanson) to occlude venous outflow from the
extremity. A wrist cuff was inflated to suprasystolic pressures
1 min before each measurement to exclude the hand
circulation (22). Flow measurements were recorded for
approximately 7 s every 15 s; seven readings were obtained
for each mean value. All blood pressures (BPs) were
recorded directly from the intra-arterial catheter after each
flow measurement. Heart rate was recorded from an ECG
lead.
Because of the prolonged infusion time required to assess
the hemodynamic effect of the different substances and their
relatively long-lasting effects, in each patient different stud-
ies were performed on separate days at least one week apart
in random sequence. Throughout all studies, volumes in-
fused were matched by administration of variable amounts
of saline.
Assessment of vascular responses to ETA receptor block-
ade in normal subjects and hypercholesterolemic pa-
tients. Basal measurements were obtained after a 15-min
infusion of saline at 1 ml/min. Then, BQ-123 (Peninsula
Laboratories; Belmont, California), a synthetic peptide with
high potency of antagonism for the ETA receptor (23), was
Abbreviations and Acronyms
BP 5 blood pressure
ET-1 5 endothelin-1
FBF 5 forearm blood flow
NHLBI 5 National Heart, Lung, and Blood Institute
NO 5 nitric oxide
Table 1. Clinical Characteristics of the Study Subjects*
Normal Control
Subjects
Hypercholesterolemic
Patients p Value
Gender (m/f) 8/4 9/3 0.75
Age (yr) 51 6 2 55 6 2 0.08
Smoking (y/n) 0/12 1/11 0.75
MAP (mm Hg) 86 6 2 91 6 2 0.15
FBF (ml/min/dl) 2.9 6 0.2 2.8 6 0.3 0.92
Total cholesterol (mg/dl) 164 6 8 292 6 10 , 0.001
LDL cholesterol (mg/dl) 101 6 10 223 6 9 , 0.001
HDL cholesterol (mg/dl) 49 6 7 43 6 3 0.39
Triglycerides (mg/dl) 92 6 20 205 6 42 0.03
*FBF 5 forearm blood flow; HDL 5 high density lipoprotein; LDL 5 low density lipoprotein; MAP 5 mean arterial pressure.
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infused at 100 nmol/min (100 nmol/ml solution). This dose
results in an intravascular concentration approximately 10-
fold higher than the pA2 (negative logarithm of the molar
concentration of antagonist that causes a twofold parallel
shift to the right of the concentration-response curve) at the
ETA receptor (23), and it has been previously shown to
effectively counteract the vasoconstrictor effect of an ET-1
infusion in the human forearm (24). BQ-123 was given for
60 min (1 ml/min infusion rate), and forearm blood flow
(FBF) was measured every 10 min.
Assessment of vascular responses to endothelin-1 in
normal subjects and hypercholesterolemic patients. To
ascertain whether there is a difference in vascular sensi-
tivity to the hemodynamic effects of ET-1 between
hypercholesterolemic patients and normal control sub-
jects, experiments were performed to compare the vaso-
motor responses to exogenous ET-1 in the two groups.
To this end, after basal measurements were obtained,
normal subjects and hypercholesterolemic patients re-
ceived an intra-arterial infusion of ET-1 (Bachem Inc.;
Torrens, California; 5 pmol/ml solution) at 5 pmol/min
(1 ml/min infusion rate) for 60 min. Forearm blood flow
was measured at 10-min intervals.
Comparison of vascular responses to selective ETA re-
ceptor blockade and nonselective ETA/ETB blockade in
hypercholesterolemic patients. In 6 of the 12 hypercho-
lesterolemic patients, the infusion of BQ-123 was ex-
tended for another 60 min (total infusion time: 120 min)
at the same dose and infusion rate as indicated above,
with repeated measurements of FBF every 10 min. On a
different occasion, these six patients, following the infu-
sion of BQ-123 for 60 min, received co-infusion of
BQ-123 and BQ-788 for another 60 min with measure-
ments of FBF every 10 min. BQ-788 (Peninsula Labo-
ratories; 50 nmol/ml solution) is a synthetic and highly
selective antagonist of ETB receptors (25) and was given
at 50 nmol/min (1 ml/min infusion rate). The dose of
BQ-788 was selected to achieve a local concentration in
the forearm more than 10-fold higher than the pA2 at the
ETB receptor (25).
Statistical analysis. Two means were compared by paired
or unpaired t test, as appropriate. Within each group, the
effect of ET-1 receptor blockade on basal FBF was assessed
by one-way analysis of variance for repeated measures.
Comparison of the response to ET-1 and ET-1 receptor
blockade between the two groups was performed with
two-way analysis of variance for repeated measures. Com-
parison of the effect of selective ETA blockade vs. combined
ETA/ETB blockade in hypercholesterolemic patients was
performed using two-way analysis of variance for repeated
measures. Multiple comparison was performed using the
Dunnett’s test. All calculated p values are two-tailed, and a
p value ,0.05 was considered to indicate statistical signif-
icance. All group data are reported as mean 6 SEM.
RESULTS
Mean arterial pressure and heart rate did not significantly
change after infusion of any of the drugs used in the study,
thus indicating that the drug effects were limited to the
infused forearm and not extended to the systemic circula-
tion. Baseline FBF was similar in hypercholesterolemic
patients and healthy control subjects (Table 1).
Vascular responses to ETA receptor blockade in normal
subjects and hypercholesterolemic patients. In normal
subjects, BQ-123 did not significantly modify FBF (p 5
0.78). By contrast, in hypercholesterolemic patients, BQ-
123 infusion resulted in a significant vasodilator response
(p , 0.001 vs. baseline). As a result, FBF values during
selective ETA blockade were significantly higher in hyper-
cholesterolemic patients than in normal subjects (Fig. 1).
Vascular responses to endothelin-1 in normal subjects
and hypercholesterolemic patients. Endothelin-1 caused
a significant vasoconstrictor response in both hypercholes-
terolemic patients (p , 0.001 vs. baseline) and normal
control subjects (p , 0.001 vs. baseline). This effect was not
significantly different between the two groups (Fig. 2).
Vascular responses to selective ETA and nonselective
ETA/ETB blockade in hypercholesterolemic patients. In
the six hypercholesterolemic patients who received BQ-123
on two different days, the magnitude of the vasodilator
response during the initial 60 min of BQ-123 administra-
tion was not different between the two occasions (Fig. 3,
left). Prolongation of BQ-123 infusion for 2 h did not result
in any significant change in the degree of vasodilation
compared with that observed after 60 min (p 5 0.67). By
contrast, addition of BQ-788 to BQ-123 progressively
Figure 1. Graph showing FBF responses to intra-arterial infusion of
BQ-123 (100 nmol/min) in normal subjects and hypercholesterolemic
patients. Values represent mean 6 SEM. The p value refers to the
comparison between the two groups in forearm blood flow changes from
baseline during selective ETA blockade by analysis of variance. There was
no significant interaction between diagnosis (normal or hypercholester-
olemic) and time of infusion.
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blunted the vasodilation induced by BQ-123 alone, with
return of FBF values to levels similar to those recorded at
baseline (3.6 6 0.7 ml/min/dl after combination of BQ-123
and BQ-788 vs. 3.2 6 0.6 ml/min/dl at baseline; p 5 0.28).
As a result, FBF values were significantly higher during
selective ETA than during nonselective ETA/ETB blockade
(Fig. 3, right).
DISCUSSION
The present study demonstrates that selective blockade of
ETA receptors results in a vasodilator effect in patients with
hypercholesterolemia but not in control subjects. These
findings suggest that ETA-dependent vasoconstrictor tone
is enhanced in hypercholesterolemic patients.
Mechanisms of increased endothelin-1 activity in hyper-
cholesterolemia. Different possibilities may explain this
increased ETA-dependent vasoconstriction in hypercholes-
terolemic patients, including increased availability of ET-1
at the ETA receptor level or enhanced susceptibility of blood
vessels to the vasoconstrictor effect of ET-1 due to, for
example, upregulation of ETA receptors. In order to identify
which mechanism may be operative in hypercholesterol-
emia, we compared vascular responsiveness to administra-
tion of exogenous ET-1 in patients and control subjects.
Our results indicate that the vasoconstrictor effect of ET-1
is not different between the two groups, thereby suggesting
that the difference in the hemodynamic effect of ETA
antagonism is not dependent on increased sensitivity of
hypercholesterolemic vessels to the vasoconstrictor effect of
ET-1. An alternative explanation to our findings is an
enhanced endogenous production of ET-1 which, in turn,
might be related to a stimulatory effect of low-density
lipoproteins on endothelial synthesis and release of the
peptide (16). Finally, we cannot exclude that upregulation of
both ET-1 receptor subtypes is present in hypercholester-
olemia, leading to a balanced hemodynamic effect, which
could explain the similar vasomotor response to exogenous
ET-1 in patients and control subjects.
Role of ETB-mediated vasodilation. The vasodilator re-
sponse to selective ETA blockade observed in hypercholes-
terolemic patients was reversed by superimposing ETB
receptor antagonism, suggesting the presence of an endog-
enous ETB-mediated vasodilator tone that becomes pre-
dominant when ETA receptors are blocked. These results
are in keeping with those previously reported by other
investigators (9) who observed that, in human resistance
arteries in vivo, ETB receptor antagonism on a background
of ETA antagonism blunts the vasodilator response induced
by selective ETA blockade. At the same time, these findings
differ from those previously observed in our laboratory in
patients with essential hypertension (26) in whom nonse-
lective ETA and ETB receptor antagonism results in further
enhancement of the vasodilator response to selective ETA
blockade. These observations suggest that ETB-mediated
vasodilation is impaired in hypertensive patients, whereas in
hypercholesterolemia, this mechanism is preserved and par-
ticipates in determining the overall hemodynamic effect of
endogenous ET-1. Although in this study we did not
investigate the precise mechanism underlying ETB-
mediated vasodilation, previous reports have demonstrated
Figure 2. Graph showing FBF responses to endothelin-1 (5 pmol/min) in
control subjects and hypercholesterolemic patients. Values represent
mean 6 SEM. The p value refers to the difference between the two groups
in FBF response to endothelin-1 infusion by analysis of variance.
Figure 3. Graph showing FBF responses to intra-arterial infusion of
BQ-123 (100 nmol/min) for 2 h (open circles) and to BQ-123 alone for 1 h
followed by the combination with BQ-788 (50 nmol/min) for another hour
(closed circles) in six hypercholesterolemic patients. Values represent
mean 6 SEM. The p value refers to the comparison in FBF changes
during selective ETA blockade between the two different occasions (left)
and during nonselective ETA/ETB blockade vs. selective ETA blockade
(right) by analysis of variance. In the latter comparison, there was no
significant interaction between treatment (BQ-123 alone vs. combination
of BQ-123 and BQ-788) and time of infusion.
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that in human peripheral resistance vessels, relaxation in
response to stimulation of ETB receptors is largely depen-
dent on endothelial generation of NO as it is blunted by NO
synthase inhibition with L-NMMA (9). Therefore, it is
possible that ETB-dependent NO production is impaired in
endothelial cells of hypertensive, but not hypercholester-
olemic, patients. Taken in conjunction with previous obser-
vations (27), these observations support the notion that
different mechanisms may be involved in the pathophysiol-
ogy of endothelial dysfunction in hypercholesterolemic
compared with hypertensive patients.
Role of Endothelin-1 in atherosclerosis. In our study, the
vasodilator response elicited by selective ETA blockade in
hypercholesterolemic patients, although statistically signifi-
cant, was of relatively modest magnitude. Although this
could suggest a limited role of ET-1 in the vascular
pathophysiology of hypercholesterolemia, it is possible that
ET-1 has an even greater role in vessels susceptible to
inflammation and atherosclerosis. For example, previous
studies have shown that, in atherosclerotic coronary vessels,
increased ET-1 immunoreactivity is associated predomi-
nantly with macrophages and activated smooth muscle cells
(28). These cells are unlikely to play a significant role in the
forearm microcirculatory bed, which is spared from the
atherosclerotic process. Thus, our study model could have
underestimated the true significance of ET-1 in the patho-
physiology of vascular damage in hypercholesterolemia.
Similarly, it must be noted that hypercholesterolemic pa-
tients with associated risk factors, such as diabetes and
hypertension, were excluded from the present study in order
to investigate the effect of hypercholesterolemia per se on
ET-1 activity. Because these other risk factors may also be
associated with enhanced ET-1 activity, it is possible that
our results underestimate the vascular activity of the peptide
in the general population of hypercholesterolemic patients,
who often have concomitant cardiovascular conditions.
Endothelin-1 vasoconstrictor activity in normal subjects.
By contrast with the results obtained in hypercholester-
olemic patients, selective blockade of ETA receptors did not
result in any significant change of FBF in normal control
subjects. This finding is in keeping with those previously
reported by our group (26), but is at odds with those
observed by another group of investigators who infused
BQ-123 in normal subjects (9,24,29). Because similar doses
and infusion times of BQ-123 have been used in the
different studies, these discrepancies cannot be accounted
for by differences in the study method. It is reasonable to
hypothesize that subjects showing a vasodilator response to
ETA receptor antagonism have, for some reason, higher
ET-1 production compared with those with no hemody-
namic response to ETA receptor blockade, leading in turn to
greater contribution of the peptide to the regulation of
vascular tone. This hypothesis seems supported by the
results of previous studies in experimental models, showing
that ET-1 receptor blockade is not associated with any
BP-lowering effect in the absence of increased ET-1 ex-
pression in small resistance arteries (30,31).
Implications. The finding that, in hypercholesterolemic
patients, selective ETA receptor blockade counteracts the
vasoconstrictor effects of increased endogenous ET-1 activ-
ity may have important pathophysiologic and therapeutic
implications. Thus, because of the role of ET-1 in athero-
genesis (12,13) and vascular remodeling (11), our demon-
stration of increased ET-1 generation in blood vessels of
hypercholesterolemic humans supports the notion of an
involvement of this peptide in the pathophysiology of
vascular damage in these patients. At the same time, the
present findings suggest that targeting the ET-1 system
might be potentially beneficial in preventing cardiovascular
damage in hypercholesterolemia. In this regard, selective
ETA receptor blockade appears to be preferable to nonse-
lective ETA/ETB blockade because the former preserves the
favorable effects of ETB receptor stimulation. However, a
recent study of epicardial coronary arteries of pigs fed a
high-cholesterol diet has shown that long-term treatment
with nonselective ET-1 blockade is equally effective as
selective ETA blockade in improving endothelium-
dependent vasodilator function (32). This would suggest
that, in vessels with early atherosclerotic lesions, both forms
of ET-1 receptor blockade are effective in preserving vas-
cular homeostasis. Further studies are needed to fully
understand the importance of ET-1 receptor subtypes under
different pathophysiologic conditions.
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